Treatment options
• Venetoclax if t(11;14)
• Talquetamab or Talquetamab combination
• Other non-BCMA immunotherapy (eg., cevostamab or GPRC5D CART on a clinical trial)
• Alkylator-based regimens (VCd, KCd, IV melphalan)
• BCMA Bispecific Combinations
• Selinexor-based regimen
• Combination chemo (VDT-PACE, CVAD, DPACE)
• Bendamustine-based regimens